Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

Published:2017-06-08 Issue:9 Volume:102 Page:1519-1529
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Gleixner Karoline V.,Schneeweiss Mathias,Eisenwort Gregor,Berger Daniela,Herrmann Harald,Blatt Katharina,Greiner Georg,Byrgazov Konstantin,Hoermann Gregor,Konopleva Marina,Waliul Islam,Cumaraswamy Abbarna A.,Gunning Patrick T.,Maeda Hiroshi,Moriggl Richard,Deininger Michael,Lion Thomas,Andreeff Michael,Valent Peter

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells;Journal of Interferon & Cytokine Research;2024-04-01

2. “Combination treatments of imatinib with astaxanthin and crocin efficiently ameliorate antioxidant status, inflammation and cell death progression in imatinib-resistant chronic myeloid leukemia cells”;Molecular Biology Reports;2024-01-16

3. Selective activation of STAT3 and STAT5 dictates the fate of myeloid progenitor cells;Cell Death Discovery;2023-07-28

4. Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia;Hematology;2023-06-22

5. HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt–autophagy pathway;Human Cell;2023-05-24